ROYALTY AND SUBLICENSE INCOME AGREEMENTRoyalty and Sublicense Income Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 27th, 2020 Company Industry JurisdictionThis ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”), dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”), (ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).
ROYALTY AND SUBLICENSE INCOME AGREEMENTRoyalty and Sublicense Income Agreement • April 1st, 2015 • Gelesis Inc • Pharmaceutical preparations • Delaware
Contract Type FiledApril 1st, 2015 Company Industry JurisdictionThis ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”), dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”), (ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).
ROYALTY AND SUBLICENSE INCOME AGREEMENTRoyalty and Sublicense Income Agreement • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 5th, 2021 Company Industry JurisdictionThis ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”), dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”), (ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).